Φορτώνει......
A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
BACKGROUND: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD). METHODS: A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of Category 3 AMD...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int J Retina Vitreous |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5088478/ https://ncbi.nlm.nih.gov/pubmed/27847612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-015-0016-5 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|